Ratings HAEMATO AG Xetra

Equities

End-of-day quote Xetra Other stock markets 04:30:00 05/02/2024 am IST			5-day change	1st Jan Change
26.2 ^EUR	-0.76%		-1.50%	-5.76%

The stock, which is currently worth 2023 to 0.25 times its sales, is clearly overvalued in comparison with peers.
Over the last twelve months, the sales forecast has been frequently revised upwards.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company sustains low margins.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HAEMATO AG	-5.76%	95.22M		-
MERCK KGAA	+7.39%	72.09B		A
KYOWA KIRIN CO. LTD.	+15.93%	9.05B		A-
SK BIOPHARMACEUTICALS CO., LTD.	-22.81%	4.4B		A-
YUHAN CORPORATION	+17.59%	4.39B		B-
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+25.93%	3.94B		-
INDIVIOR PLC	+4.64%	2.1B		B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+9.09%	1.97B	-	-
BETTA PHARMACEUTICALS CO., LTD.	-36.86%	1.87B		C-
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality